Search
Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigationalVimseltinib is a small molecule kinase inhibitor targeting colony-stimulating factor 1 receptor (CSF1R). It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. It is intended to provide a sa...
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigationalRecombinant stabilized RSV B prefusion F antigen is one component of a bivalent respiratory syncytial virus (RSV) vaccine called Abrysvo. The vaccine comprises two antigens - the other being recombinant stabilized RSV A prefusion F antig...
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
HMR4011
go.drugbank.com/drugs/DB06225ExperimentalIPL 576,092 has previously been investigated as a treatment for asthma.
Doramectin
go.drugbank.com/drugs/DB11400ExperimentalVet approvedDoramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites
Candesartan
go.drugbank.com/drugs/DB13919InvestigationalIt is available as a prodrug in the form of [candesartan cilexetil].
Tersolisib
go.drugbank.com/drugs/DB21752InvestigationalSTX-478 is under investigation in clinical trail NCT05768139 (First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Tapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalTapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake. Tapentadol was first approved by the FDA on November 20, 2008. The exten...
OC-1012
go.drugbank.com/drugs/DB05834ExperimentalOC-1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of mucositis, a serious side effect of chemotherapy and head and neck radiation therapy.
2,4-Dinitrophenol
go.drugbank.com/drugs/DB04528ExperimentalIt is also used as a metabolic stimulant. (Stedman, 26th ed)